Kamada Ltd
NASDAQ:KMDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kamada Ltd
Cash Equivalents
Kamada Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash Equivalents
$75.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
31%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash Equivalents
$314k
|
CAGR 3-Years
-81%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-27%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash Equivalents
$110.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash Equivalents
$7.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash Equivalents
$4.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Cash Equivalents
₪86k
|
CAGR 3-Years
-84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
See Also
What is Kamada Ltd's Cash Equivalents?
Cash Equivalents
75.5m
USD
Based on the financial report for Dec 31, 2025, Kamada Ltd's Cash Equivalents amounts to 75.5m USD.
What is Kamada Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
31%
Over the last year, the Cash Equivalents growth was -4%. The average annual Cash Equivalents growth rates for Kamada Ltd have been 30% over the past three years , 1% over the past five years , and 31% over the past ten years .
